Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06643260 | A Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and Efficacy | PHASE3 | NOT YET_RECRUITING | 705 | — | — | Jun 1, 2025 | Jun 1, 2028 | Apr 29, 2025 | - | — |
Improvement of psoriasis by 75% or more
Improvement of psoriasis by physicians' judgment
All adverse events occurring the trial will be recorded
| Arm | Type | Description |
|---|---|---|
| Piclidenoson treatment | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| piclidenoson | DRUG | Piclidenoson is a selective A3AR agonist, supplied as tablets. |
| Placebo | DRUG | Inactive control |
Inclusion Criteria: 1. Male or female, 18 years and above; 2. Diagnosis of moderate-to-severe chronic plaque-type psoriasis with BSA involvement ≥10%; 3. PASI score ≥12 at the Screening and Baseline visits; 4. Static PGA ≥3 at the Screening and Baseline visits; 5. Candidate for systemic treatment o...